Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept plus glucocorticosteroids versus placebo plus glucocorticosteroids for active systemic lupus erythematosus
2004-004051-19Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Abatacept plus glucocorticosteroids with Placebo plus glucocorticosteroids (2 arms). Primary endpoints: Occurrence of SLE disease flare during the 12-month treatment period, Proportion of subjects with a new clinical flare of SLE during the 1-year double-blind treatment period and 1 more. Started Mar 2005; status: terminated.
02
Drugs
abatacept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2004-004051-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004051-19.